Comprehensive Analysis of Novel Genes and Pathways Associated with Osteogenic Differentiation of Adipose Stem Cells

Qiuni Gao,1 Xiaorong Ma,2 and Zuoliang Qi3

1Department of Plastic and Cosmetic Surgery, Tongji Hospital, School of Medicine, Tongji University, Shanghai 200065, China
2Department of Plastic and Reconstructive Surgery, Xinhua Hospital, Kongjiang Road 1665, Shanghai 200092, China
3Department of Plastic and Reconstructive Surgery, Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 33 Badachu Road, Shijingshan District, Beijing 100144, China

Correspondence should be addressed to Xiaorong Ma; maxiaorong@xinhuamed.com.cn and Zuoliang Qi; public_qi@163.com

Received 31 May 2022; Accepted 20 July 2022; Published 12 September 2022

Background. Adipose-derived stem cells (ADSCs) are an important alternative source of mesenchymal stem cells (MSCs) and show great promise in tissue engineering and regenerative medicine applications. However, identifying the novel genes and pathways and finding the underlying mechanisms regulating ADSCs osteogenic differentiation remain urgent.

Methods. We downloaded the gene expression profiles of GSE63754 and GSE37329 from the Gene Expression Omnibus (GEO) Database. We derived differentially expressed genes (DEGs) before and after ADSC osteogenic differentiation, followed by Gene Ontology (GO) functional and KEGG pathway analysis and protein-protein interaction (PPI) network analysis. 211 differentially expressed genes (142 upregulated genes and 69 downregulated genes) were aberrantly expressed. GO analysis revealed that these DEGs were associated with extracellular matrix organization, protein extracellular matrix, and semaphorin receptor binding.

Conclusions. Our study provides novel genes and pathways that play important roles in regulating ADSC osteogenic differentiation, which may have potential therapeutic targets for clinic.

1. Introduction

Millions of patients around the world suffer from bone defects caused by tumors, infections, and trauma, and their repair and treatment are a major problem [1]. Over 10 million bone transplants are performed worldwide each year, and the number is still growing at a rate of 10% annually [2]. Presently, autologous bone transplantation and allogeneic bone transplantation are the two main surgical options for treating bone defects and nonunion [3, 4]. Autologous bone transplants are a common treatment for bone defects, but their use is limited due to their limited source, poor plasticity, and damaging to the donor site [5]. Allogeneic bone transplantation results in a significantly higher rate of postoperative complications, which has exceeded 30%, and includes fractures, insufficiency, and infections [6, 7].

By creating replacements for natural bone grafts, bone tissue engineering aims to address the shortcomings [8]. As well as having the ability to form on demand, it should also easy to be prepared. Several advances have been made recently, including the development of human ADSCs that can perform paracrine functions as well as multilineage differentiation [9–11]. As a result of their properties, ADSCs are especially useful in bone tissue engineering. Transplanting human ADSCs as a prospective treatment has recently received some attention [12, 13]. The treatment of bone trauma with autologous cells is therefore relatively promising. Transcriptional, posttranscriptional, and epigenetic factors regulate osteogenic differentiation of ADSCs [14]. A high-efficiency osteoinductive factor is also required as part of repairing bone tissue [15]. Wnt, PI3K/Akt, and MAPK signaling pathways were associated with osteogenic differentiation of ADSCs [16]. So, we have focused on developing osteoinductive factors that are effective. To uncover the molecular mechanisms of osteogenesis, further research is required.

ADSCs have become a hot spot in bone tissue engineering research because of their abundant sources and easy access to materials. However, the molecular biological...
Figure 1: Continued.
mechanism of osteogenic differentiation of ADSCs has not been fully elucidated [17]. With the rapid development of big data and bioinformatics, as well as the application of ADSCs in the field of clinical medicine, some scholars have carried out RNA microarray and sequencing studies on the osteogenic differentiation of ADSCs to further explore the role of these RNAs in the osteogenesis of ADSCs [18, 19]. Molecular biological mechanisms during differentiation remains elusive. Molecular biology and functional genomics utilize microarray profiling to discover genes that are upregulated or downregulated, respectively [20, 21]. Therefore, in this study, bioinformatics methods were used to screen the differentially expressed genes and their involved signaling pathways during the osteogenic differentiation of ADSCs, in order to explore the molecular biological mechanism of potential key genes during the osteogenic differentiation of ADSCs. We first identified the differentially expressed genes (DEGs) from two microarray datasets selected from Gene Expression Omnibus (GEO) database. A bioinformatics approach was used to analyze the signaling pathway involving novel genes and to construct a protein–protein interaction (PPI) network. To sum up, this study found the potential key genes and the pathways involved in the osteogenic differentiation of ADSCs by mining the data related to the osteogenic differentiation of ADSCs in GEO database. These results may provide new ideas and a basis for further experimental studies to explore the genesis, development, and molecular biological mechanism of osteogenic differentiation of ADSCs in the future.

2. Methods

2.1. Data Collection. Transcript profile data on osteogenic differentiation between ADSCs and noninduced ADSCs were derived from NCBI GEO databases (http://www.ncbi.nlm.nih.gov/geo/).

GSE63754 (3 undifferentiated ADSCs and 3 osteogenic differentiated ADSCs) and GSE37329 (3 ADSCs and 2 ADSC-derived osteocytes) are the accession numbers for the collections. All of these ADSCSDs were collected from human tissues and underwent osteogenic induction.

2.2. Identification of Differentially Expressed Gene. R software and Bioconductor packages were applied to data mining and statistical analyses. The Limma package was subsequently used for identifying DEGs.

\[ P < 0.05 \text{ and log2 fold change (log2FC) } > 1 \text{ or } < -1 \]

were considered as the cutoff values for DEGs to be considered statistically significant. R software was used to produce heat maps of common significant differentially expressed genes between GSE63754 and GSE37329.

2.3. GO and KEGG Enrichment Analysis. GSEA was performed using GSEA 3.0 (http://www.broadinstitute.org/gsea/). Geneset with a \( P \) value less than 0.05 was considered to be significantly enriched. GO enrichment analysis was performed using the Gene Ontology Consortium Enrichment analysis tool (http://www.geneontology.org). To analyze the enriched biological processes (BPs), cellular components (CCs), molecular functions (MFs), and pathways of DEGs, GO analysis and KEGG pathway enrichment analysis were performed with the online tools DAVID (https://david.ncifcrf.gov/) and MetADSC- saper (http://metADSCsape.org).

2.4. PPI Network Construction. STRING database (http://string-db.org) and Cytoscape software (Version 3.4.0) were used to identify 142 upregulated DEGs and 69 downregulated DEGs. The network was visualized using Cytoscape, a widely-used tool for exploring interactions among biomolecules, including proteins and genes.

2.5. Statistical Methods. These statistics were generated using the R software and were two-sided. \( P \) values less than 0.05 were considered statistically significant.

3. Results

3.1. DEGs of GSE63754 and GSE37329. Differential gene expression analyses were visualized by volcano plots. To explore the biological classification of the DEGs overlapping in the dataset, all genes were identified in the two datasets using DAVID and MetADSCsape software. The genes are commonly regulated \( (P < 0.05 \text{ and log2 fold change (log2FC) } > 1 \text{ or } < -1) \) in GSE63754. Then, we compared the gene expression
Figure 2: Continued.
profiles between ADSCs before and after osteogenic induction by using GSEA. Figures 1(a)–1(c) show DEGs in GSE63754. Figures 1(d)–1(f) show DEGs in GSE37329.

3.2. GO and KEGG Pathway Enrichment Analysis. Through GO and KEGG analysis, we found that DEGs of GSE63754, extracellular matrix organization, ossification, bone mineralization, regulation of inflammatory response, and bone remodeling were mainly showed enrichment in the biological process (BP) categories. As for cellular component (CC) categories, collagen-containing extracellular matrix, high-density lipoprotein particle, plasma lipoprotein particle, plasma lipoprotein particle, and protein-lipid complex were detected; and in molecular function (MF), receptor ligand activity, extracellular matrix structural constituent, growth factor activity, Wnt-protein binding, and cytokine receptor binding. With regard to KEGG pathway, cytokine-cytokine receptor interaction, ECM-receptor interaction, PI3K-Akt signaling pathway, PPAR

**Table 1: Gene Ontology analyses of upregulated DEGs.**

| Ontology | ID       | Description                                                                 | Gene Ratio | Bg Ratio | P value  | P adjust | Q value |
|----------|----------|------------------------------------------------------------------------------|------------|----------|-----------|----------|---------|
| BP       | GO: 1903532 | Positive regulation of secretion by cell                                   | 13/130     | 399/18670 | 4.36e-06  | 0.009    | 0.008   |
| BP       | GO: 0051047 | Positive regulation of secretion                                             | 13/130     | 428/18670 | 9.27e-06  | 0.009    | 0.008   |
| BP       | GO: 0002532 | Production of molecular mediator involved in inflammatory response          | 6/130      | 72/18670  | 1.09e-05  | 0.009    | 0.008   |
| BP       | GO: 0070542 | Response to fatty acid                                                       | 6/130      | 86/18670  | 3.03e-05  | 0.014    | 0.012   |
| BP       | GO: 0050727 | Regulation of inflammatory response                                          | 13/130     | 485/18670 | 3.44e-05  | 0.014    | 0.012   |
| CC       | GO: 0034358 | Lipoprotein particle                                                        | 4/134      | 37/19717  | 1.13e-04  | 0.012    | 0.011   |
| CC       | GO: 1990777 | Lipoprotein particle                                                        | 4/134      | 37/19717  | 1.13e-04  | 0.012    | 0.011   |
| CC       | GO: 0032994 | Protein-lipid complex                                                       | 4/134      | 39/19717  | 1.39e-04  | 0.012    | 0.011   |
| CC       | GO: 0099061 | Integral component of postsynaptic density membrane                         | 4/134      | 50/19717  | 3.69e-04  | 0.017    | 0.015   |
| CC       | GO: 0099146 | Intrinsic component of postsynaptic density membrane                        | 4/134      | 53/19717  | 4.61e-04  | 0.017    | 0.015   |
| MF       | GO: 0016709 | Oxidoreductase activity                                                      | 4/130      | 39/17697  | 1.87e-04  | 0.065    | 0.058   |
| MF       | GO: 0004745 | Retinol dehydrogenase activity                                               | 3/130      | 20/17697  | 4.03e-04  | 0.070    | 0.063   |
| MF       | GO: 0004497 | Monooxygenase activity                                                       | 5/130      | 99/17697  | 8.16e-04  | 0.094    | 0.084   |
| KEGG     | hsa00982   | Drug metabolism-cytochrome P450                                                | 8/66       | 71/8076   | 9.12e-08  | 1.48e-05 | 1.40e-05|
| KEGG     | hsa00350   | Tyrosine metabolism                                                          | 5/66       | 36/8076   | 9.69e-06  | 7.85e-04 | 7.45e-04|
| KEGG     | hsa00071   | Fatty acid degradation                                                        | 4/66       | 44/8076   | 4.32e-04  | 0.023    | 0.022   |
| KEGG     | hsa04979   | Cholesterol metabolism                                                       | 4/66       | 50/8076   | 7.07e-04  | 0.029    | 0.027   |
| KEGG     | hsa00830   | Retinol metabolism                                                           | 4/66       | 68/8076   | 0.002     | 0.073    | 0.069   |

**Figure 2:** GO and KEGG pathway enrichment analysis. (a–h) Gene Ontology (GO) analysis and enriched KEGG signaling pathways were selected to demonstrate the primary biological actions of major potential genes. Colors represent the significance of differential enrichment, the size of the circles represents the number of genes, the larger the circle, the greater the number of genes. In the enrichment result, $P < 0.05$ or FDR $< 0.05$ is considered to be a meaningful pathway (enrichment score with $-\log_{10}(P)$ of more than 1.3). BP: biological process; CC: cellular component; MF: molecular function.
signaling pathway, and cholesterol metabolism were the top pathways involved in the osteogenic differentiation of ADSCs (Figures 2(a)–2(d)). Gene Ontology analyses of upregulated and downregulated DEGs are listed in Tables 1 and 2.

In GSE37329 dataset, regulation of blood pressure, chemokine production, regulation of inflammatory response, regulation of chemokine production, and regulation of fat cell differentiation were detected in BP. In CC categories, we found collagen-containing extracellular matrix, synaptic membrane, presynapse, exocytic vesicle, and transport vesicle were mainly shown. As for MF, glycosaminoglycan binding, G protein-coupled peptide receptor activity, peptide receptor activity, Wnt-protein binding, and extracellular matrix structural constituent were figured out. The results of KEGG pathway demonstrated that drug metabolism–cytochrome P450, tyrosine metabolism, neuroactive ligand-receptor interaction, and vascular smooth muscle contraction were important in the osteogenic differentiation of ADSCs (Figures 2(e)–2(h)).

3.3. Overlapping DEGs of Datasets. The commonly and differentially expressed genes in GSE63754 and GSE37329 during osteogenic differentiation of ADSCs were identified ($P < 0.05$ and log2 fold change ($\log2 FC$) > 1 or $< -1$). To investigate the biological classification of the 142-overlapping upregulated DEGs and 69-overlapping downregulated DEGs, DAVID and MetADSCsape software packages were used to identify genes in the two datasets. In 142 upregulated overlapping DEGs, we found that positive regulation of secretion and positive regulation and fatty acid degradation were in the center of GO network. In 69-overlapping downregulated DEGs, striated muscle tissue development and muscle tissue development were significantly different (Figures 3(a)–3(d)).

3.4. Key Candidate Gene Identification with DEG PPI Network. Based on the STRING online database and Cytoscape software, DEG protein–protein interaction (PPI) network complex was constructed. We collected 142-overlapping upregulated DEGs and 69-overlapping downregulated DEGs to create the PPI network. The central node genes might potentially play an important role in regulating ADSC osteogenic differentiation (Figure 4).

4. Discussion

In the field of tissue engineering, the use of biocompatible scaffolds has increased in recent years [22]. The ability to self-renew, the proliferation potential, and the multipotency of ADSCs make them attractive for regenerative medicine applications [23, 24]. Since ADSCs are readily available and easy to obtain in large quantities, they have become promising seed cells for bone tissue engineering [25]. In order for ADSC-based therapies to be successful in vivo, they must be paired with a substance that facilitates their osteogenic differentiation in vivo [26]. Thus, it is critical that we understand the molecular mechanisms that underlie osteogenic differentiation in ADSCs.

We firstly analyse GSE63754 (3 undifferentiated ADSCs and 3 osteogenic differentiated ADSCs) and GSE37329 (3 ADSCs and 2 ADSC-derived osteocytes). Because of this study, we found 211 significant DEGs common to both microarrays (142 upregulated and 69 downregulated). The most enrichment is extracellular matrix organization in the BP category. The extracellular matrix is an active factor in cellular differentiation, and modifying its composition can greatly influence osteogenic differentiation of mesenchymal stem cells (Hwang et al., 2015). Other BP, such as ossification, bone mineralization, regulation of inflammatory response, and bone

| Ontology | ID | Description | GeneRatio | BgRatio | P value | P.adjust | Q value |
|----------|----|-------------|-----------|---------|---------|-----------|---------|
| BP       | GO:0010721 | Negative regulation of cell development | 12/66 | 344/18670 | 2.55e-09 | 5.10e-06 | 3.85e-06 |
| BP       | GO:0060537 | Muscle tissue development | 12/66 | 408/18670 | 1.71e-08 | 1.71e-05 | 1.29e-05 |
| BP       | GO:0014706 | Striated muscle tissue development | 11/66 | 390/18670 | 1.10e-07 | 7.34e-05 | 5.54e-05 |
| BP       | GO:0050768 | Negative regulation of neurogenesis | 9/66 | 295/18670 | 9.14e-07 | 4.57e-04 | 3.45e-04 |
| BP       | GO:0051961 | Negative regulation of nervous system development | 9/66 | 315/18670 | 1.57e-06 | 6.29e-04 | 4.75e-04 |
| CC       | GO:0005913 | Cell-cell adherens junction | 4/66 | 117/19717 | 6.39e-04 | 0.026 | 0.024 |
| CC       | GO:0045121 | Membrane raft | 6/66 | 315/19717 | 6.44e-04 | 0.026 | 0.024 |
| CC       | GO:0098857 | Membrane microdomain | 6/66 | 316/19717 | 6.55e-04 | 0.026 | 0.024 |
| CC       | GO:0098589 | Membrane region | 6/66 | 328/19717 | 7.95e-04 | 0.026 | 0.024 |
| CC       | GO:0016342 | Catenin complex | 2/66 | 29/19717 | 0.004 | 0.092 | 0.084 |
| MF       | GO:0045499 | Chemorepellent activity | 4/63 | 27/17697 | 2.41e-06 | 5.22e-04 | 4.61e-04 |
| MF       | GO:0001158 | Enhancer sequence-specific DNA binding | 5/63 | 119/17697 | 6.50e-05 | 0.005 | 0.005 |
| MF       | GO:0030215 | Semaphorin receptor binding | 3/63 | 23/17697 | 7.24e-05 | 0.005 | 0.005 |
| MF       | GO:0035326 | Enhancer binding | 5/63 | 133/17697 | 1.10e-04 | 0.006 | 0.005 |
| MF       | GO:0005539 | Glycosaminoglycan binding | 6/63 | 229/17697 | 1.61e-04 | 0.007 | 0.006 |
| KEGG     | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 5/40 | 143/8076 | 6.48e-04 | 0.064 | 0.061 |
| KEGG     | hsa04350 | TGF-beta signaling pathway | 4/40 | 94/8076 | 0.001 | 0.064 | 0.061 |
remodeling, were also showed enrichment. ADSCSs undergo osteogenic differentiation, thus, a regulation of genes negatively related to cell proliferation is observed.

In CC categories, collagen-containing extracellular matrix, high-density lipoprotein particle, plasma lipoprotein particle, plasma lipoprotein particle, and protein-lipid complex showed the highest enrichment score. It is interesting to note that two of the top eight CCs that are highly associated with ADSCS osteogenic differentiation are either located in the extracellular space or are located in the cell membrane, indicating that cell-to-cell signaling plays a crucial role in osteogenic differentiation. In MF categories, except chemorepellent activity, enhancer sequence-specific DNA binding, and semaphorin receptor binding, Wnt-protein binding and Wnt-activated receptor activity are most important factors. ADSCs differentiate into osteoblasts through Wnt proteins, and bone formation occurs via these proteins. It is possible that disrupting Wnt signaling pathway might significantly affect bone regeneration and remodeling [27–29]. ADSCs differ in their osteogenic differentiation in response
to a variety of signaling pathways, including ERK1/2, Wnt, PI3K/Akt, and BMP-Smad. These proteins enable ADSCs to differentiate into osteoblasts and lead to bone formation. In KEGG pathway, the top significantly changed pathways of upregulated genes are related to drug metabolism-cytochrome P450, tyrosine metabolism, fatty acid degradation, cholesterol metabolism, retinol metabolism, and PPAR signaling pathway. ADSCs that differentiate into osteoblasts have downregulated genes influenced by the adipogenesis pathway.

**Figure 4:** Key candidate gene identification with DEG PPI network. PPI network of the common significant differentially expressed genes was constructed. A total of 142-overlapping upregulated DEGs and 69-overlapping downregulated DEGs were identified by Cytoscape. PPI: protein–protein interaction.
ADSCs were targeted by several pathways which affected osteogenic differentiation and, as a result, affected bone formation. In our study, we constructed a PPI network which is composed of the associated genes. PODXL is a negatively charged sialic acid glycoprotein, belonging to the type I transmembrane glycoprotein, which has been reported to be associated with poor prognosis in oral squamous cell carcinoma, colon cancer, glioblastoma, and breast cancer and has an impact on cell adhesion and migration. It has a promoting effect, and PODXL is an important condition for maintaining the stability of the pod cytoskeleton [30]. SEMA3D is a member of the class III semaphorin family and is a marker of osteoarthritis. Class III semaphorins are involved in normal bone homeostasis and bone pathology and have a complex relationship between osteoblasts and osteoclasts which has the potential to treat bone disease [31]. The ADGRG6 single nucleotide polymorphism is associated with human height, and its deletion in osteoblasts during osteogenic induction, RERG expression was downregulated in calvarial osteoblasts; and during osteogenic induction, RERG expression was downregulated in calvarial osteoblasts and upregulated in femoral osteoblasts [20]. The osteocytes of the skull are fundamentally different from those of the femur and respond differently to a range of stimuli. These site-specific differences may have important implications in developing strategies to address metabolic bone disease [36]. APCDD1 is an inhibitor of Wnt signaling pathway, which can promote the adipogenic differentiation and lipid anabolism of bone marrow stromal cells [37]. NRCAM may modulate geometric parameters of the femoral neck and contribute to an improved understanding of osteoporosis and pathophysiological mechanisms [38, 39]. The target genes supported by these literatures are related to bone homeostasis, osteogenic differentiation, bone diseases, and metabolism, which supports the feasibility of this study to explore the underlying molecular mechanisms during the osteogenic differentiation of adipose-derived stem cells [40].

The drawback of our study is the lack of functional cellular and animal experiments for validation to explore the occurrence, development, and molecular biology of osteogenic differentiation of ADSCs. In conclusion, based on two transcript profile data on osteogenic differentiation between ADSCs and noninduced ADSC datasets and comprehensive analysis, we have identified several genes and pathways that could be crucial to osteogenic differentiation of ADSCs. Understanding of how ADSCs differentiate into osteoblasts could be improved significantly by our new findings. Moreover, manipulation of these genes and pathways may lead to bone regeneration and tissue engineering.

Data Availability

All the data in this manuscript can be acquired by request.

Conflicts of Interest

The authors declare that they there is no conflicts of interest.

References

[1] J. H. Cheng, C. C. Hsu, S. L. Hsu et al., “Adipose-derived mesenchymal stem cells-conditioned medium modulates the expression of inflammation induced bone morphogenetic protein-2, -5 and -6 as well as compared with shockwave therapy on rat knee osteoarthritis,” *Biomedicine*, vol. 9, no. 10, 2021.

[2] X. Liu, G. Zhao, X. Huo et al., “Adipose-derived stem cells facilitate ovarian tumor growth and metastasis by promoting epithelial to mesenchymal transition through activating the TGF-β pathway,” *Frontiers in Oncology*, vol. 11, article 756011, 2021.

[3] A. Soltani, M. Moradi, A. R. Nejad et al., “Adipose-derived stem cells: potentials, availability and market size in regenerative medicine,” *Current Stem Cell Research & Therapy*, vol. 17, 2022.

[4] M. Maj, Ł. Kaziemierski, K. Balik et al., “Bladder cancer cells exert pleiotropic effects on human adipose-derived stem cells,” *Life (Basel)*, vol. 12, no. 4, 2022.

[5] Q. Liu, L. Cen, S. Yin et al., “A comparative study of proliferation and osteogenic differentiation of adipose-derived stem cells on akermaite and β-TCP ceramics,” *Biomaterials*, vol. 29, no. 36, pp. 4792–4799, 2008.

[6] Y. Ye, Y. Du, F. Guo, C. Gong, K. Yang, and L. Qin, “Comparative study of the osteogenic differentiation capacity of human bone marrow- and human adipose-derived stem cells under cyclic tensile stretch using quantitative analysis,” *International Journal of Molecular Medicine*, vol. 30, no. 6, pp. 1327–1334, 2012.

[7] K. R. Hixon, D. B. Katz, J. A. McKenize, A. N. Miller, F. Gulak, and M. J. Silva, “Cryogel scaffold-mediated delivery of adipose-derived stem cells promotes healing in murine model of atrophic non-union,” *Frontiers in Bioengineering and Biotechnology*, vol. 10, article 851904, 2022.

[8] W. Oliva-Olivera, A. L. Gea, S. Lhamyani et al., “Differences in the osteogenic differentiation capacity of omental adipose-derived stem cells in obese patients with and without metabolic syndrome,” *Endocrinology*, vol. 156, no. 12, pp. 4492–4501, 2015.

[9] J. Fan, J. Dai, F. Lu, and Y. Zhang, “Editorial: regulation mechanism of adipose-derived stem cells in differentiation and translation,” *Frontiers in Physiology*, vol. 13, article 852275, 2022.

[10] K. Kornicka, K. Marycz, K. A. Tomaszewski, M. Maredziak, and A. Smieszek, “The effect of age on osteogenic and adipogenic differentiation potential of human adipose derived stromal stem cells (hASCs) and the impact of stress factors in the course of the differentiation process,” *Oxidative Medicine and Cellular Longevity*, vol. 2015, Article ID 309169, 2015.

[11] W. K. Ko, D. N. Heo, H. J. Moon et al., “The effect of gold nanoparticle size on osteogenic differentiation of adipose-derived stem cells,” *Journal of Colloid and Interface Science*, vol. 438, pp. 68–76, 2015.

[12] S. E. Kim, Y. P. Yun, K. S. Shim, K. Park, S. W. Choi, and D. H. Suh, “Effect of lactoferrin-impregnated porous polylactide-co-glycolide (PLGA) microspheres on osteogenic differentiation of rabbit adipose-derived stem cells (rADSCs),” *Colloids and Surfaces, B, Biointerfaces*, vol. 122, pp. 457–464, 2014.
[13] L. Xia, K. Lin, X. Jiang et al., "Effect of nano-structured bioceramic surface on osteogenic differentiation of adipose-derived stem cells," Biomaterials, vol. 35, no. 30, pp. 8514–8527, 2014.

[14] M. Nii, J. H. Lai, M. Keeney et al., "The effects of interactive mechanical and biochemical niche signaling on osteogenic differentiation of adipose-derived stem cells using combinatorial hydrogels," Acta Biomaterialia, vol. 9, no. 3, pp. 5475–5483, 2013.

[15] J. Li, Z. Li, S. Wang, J. Bi, and R. Huo, "Exosomes from human adipose-derived mesenchymal stem cells inhibit production of extracellular matrix in keloid fibroblasts via downregulating transforming growth factor-β2 and Notch-1 expression," Bioengineered, vol. 13, no. 4, pp. 8515–8525, 2022.

[16] Y. K. Jeon, M. J. Bae, J. I. Kim et al., "Expression of glucoagon-like peptide 1 receptor during osteogenic differentiation of adipose-derived stem cells," Endocrinol Metab (Seoul), vol. 29, no. 4, pp. 567–573, 2014.

[17] X. Shi, X. Shao, B. Liu et al., "Genome-wide screening of functional long noncoding RNAs in the epithelial adipose tissues of atrial fibrillation," Biochimica et Biophysica Acta - Molecular Basis of Disease, vol. 1866, no. 7, article 165757, 2020.

[18] S. Y. Choi, M. S. Song, P. D. Ryu, A. T. Lam, S. W. Joo, and S. Y. Lee, "Gold nanoparticles promote osteogenic differentiation in human adipose-derived mesenchymal stem cells through the Wnt/β-catenin signaling pathway," International Journal of Nanomedicine, vol. 10, pp. 4383–4392, 2015.

[19] X. Hu, X. Zhang, L. Dai et al., "Histone deacetylase inhibitor trichostatin A promotes the osteogenic differentiation of rat adipose-derived stem cells by altering the epigenetic modifications on Runx2 promoter in a BMP signaling-dependent manner," Stem Cells and Development, vol. 22, no. 2, pp. 248–255, 2013.

[20] L. De Girolamo, M. F. Sartori, E. Arrigoni et al., "Human adipose-derived stem cells as future tools in tissue regeneration: osteogenic differentiation and cell-scaffold interaction," The International Journal of Artificial Organs, vol. 31, no. 6, pp. 467–479, 2008.

[21] A. C. de Paula, A. A. C. Zonari, T. M. M. Martins et al., "Human serum is a suitable supplement for the osteogenic differentiation of human adipose-derived stem cells seeded on poly-3-hydroxybutyrate-co-3-hydroxyvalerate scaffolds," Tissue Engineering. Part A, vol. 19, no. 1-2, pp. 277–289, 2013.

[22] M. Brisset, R. Ben Yaou, R. Y. Carlier et al., "X-linked Emery-Dreifuss muscular dystrophy manifesting with adult onset axial weakness, camptocormia, and minimal joint contractures," Neuromuscular Disorders, vol. 29, no. 9, pp. 678–683, 2019.

[23] W. Jiang, J. Zhang, X. Zhang, C. Fan, and J. Huang, "VAP-PPLGA microspheres (VAP-PPLGA) promote adipose-derived stem cells (ADSCs)-induced wound healing in chronic skin ulcers in mice via PI3K/Akt/HIF-1α pathway," Bioengineered, vol. 12, no. 2, pp. 10264–10284, 2021.

[24] X. Liu, Q. Feng, A. Bachhuka, and K. Vasiliev, "Surface modification by allylamine plasma polymerization promotes osteogenic differentiation of human adipose-derived stem cells," ACS Applied Materials & Interfaces, vol. 6, no. 12, pp. 9733–9741, 2014.

[25] R. Vij, K. A. Stebbings, H. Kim, H. Park, and D. Chang, "Safety and efficacy of autologous, adipose-derived mesenchymal stem cells in patients with rheumatoid arthritis: a phase I/IIa, open-label, non-randomized pilot trial," Stem Cell Research & Therapy, vol. 13, no. 1, p. 88, 2022.

[26] H. Gu, Z. Huang, X. Yin et al., "Role of c-Jun N-terminal kinase in the osteogenic and adipogenic differentiation of human adipose-derived mesenchymal stem cells," Experimental Cell Research, vol. 339, no. 1, pp. 112–121, 2015.

[27] B. Krief, S. W. Algor, I. Nakdimon et al., "Retinal lineage therapeuticspecific effect of human orbital and abdominal adipose-derived mesenchymal stem cells," Stem Cells International, vol. 2021, Article ID 702247, 15 pages, 2021.

[28] S. Yang, S. Guo, S. Tong, and X. Sun, "Promoting osteogenic differentiation of human adipose-derived stem cells by altering the expression of exosomal miRNA," Stem Cells International, vol. 2019, Article ID 1351860, 15 pages, 2019.

[29] M. Sattary, M. Rafienia, M. Kazemi, H. Salehi, and M. Mahmoudzadeh, "Promoting effect of nano hydroxyapatite and vitamin D3 on the osteogenic differentiation of human adipose-derived stem cells in polycaprolactone/gelatin scaffold for bone tissue engineering," Materials Science & Engineering. C, Materials for Biological Applications, vol. 97, pp. 141–155, 2019.

[30] L. Feng, J. Zhou, B. Xia, and B. F. Tian, "The positive effect of TET2 on the osteogenic differentiation of human adipose-derived mesenchymal stem cells," Cellular Reprogramming, vol. 22, no. 1, pp. 3–13, 2020.

[31] S. H. Hong, J. Nam, H. J. Kim, and J. J. Yoo, "Platelet-rich plasma pretreatment on grit-blasted titanium alloy for enhanced osteogenic differentiation of human adipose-derived stem cells," Clinics in Orthopedic Surgery, vol. 11, no. 3, pp. 361–368, 2019.

[32] G. Ramazzotti, R. Fiume, F. Chiarini et al., "Phospholipase C-β1 interacts with cyclin E in adipose-derived stem cells osteogenic differentiation," Advances in biological regulation, vol. 71, pp. 1–9, 2019.

[33] G. F. Petersen, B. J. Hilbert, G. D. Trope, W. H. Kalle, and P. M. Strappe, "A paper-based scaffold for enhanced osteogenic differentiation of equine adipose-derived stem cells," Biotechnology Letters, vol. 37, no. 11, pp. 2321–2331, 2015.

[34] S. M. Mihaila, A. K. Gaharwar, R. L. Reis, A. Khademhosseini, A. P. Marques, and M. E. Gomes, "The osteogenic differentiation of SSEA-4 sub-population of human adipose-derived stem cells using silicate nanoparticles," Biomaterials, vol. 35, no. 33, pp. 9087–9099, 2014.

[35] Y. Luo, R. Ge, H. Wu et al., "The osteogenic differentiation of human adipose-derived stem cells is regulated through the let-7i-3p/LEF1/β-catenin axis under cyclic strain," Stem Cell Research & Therapy, vol. 10, no. 1, p. 339, 2019.

[36] B. Yan, S. Lv, P. Tong et al., "Intra-articular injection of adipose-derived stem cells ameliorates pain and cartilage anabolism/catabolism in osteoarthritis: preclinical and clinical evidences," Frontiers in Pharmacology, vol. 13, article 854025, 2022.

[37] M. Nahrendorf and F. K. Swirski, "Lifestyle effects on hematoipoiesis and atherosclerosis," Circulation Research, vol. 116, no. 5, pp. 884–894, 2015.

[38] L. Labusca, D. D. Herea, A. Emanuela Minuti et al., "Magnetic nanoparticles and magnetic field exposure enhances chondrogenesis of human adipose derived mesenchymal stem cells but not of Wharton jelly mesenchymal stem cells," Frontiers in Bioengineering and Biotechnology, vol. 9, article 737132, 2021.
[39] L. Lv, Y. Liu, P. Zhang et al., “The nanoscale geometry of TiO$_2$ nanotubes influences the osteogenic differentiation of human adipose-derived stem cells by modulating H3K4 trimethylation,” *Biomaterials*, vol. 39, pp. 193–205, 2015.

[40] M. S. Carvalho, L. Alves, I. Bogalho, J. M. S. Cabral, and C. L. da Silva, “Impact of donor age on the osteogenic supportive capacity of mesenchymal stromal cell-derived extracellular matrix,” *Frontiers in Cell and Development Biology*, vol. 9, article 747521, 2021.